GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (STU:4B70) » Definitions » Shiller PE Ratio

Antibe Therapeutics (STU:4B70) Shiller PE Ratio : (As of Jun. 23, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Antibe Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Antibe Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Antibe Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics Shiller PE Ratio Chart

Antibe Therapeutics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Antibe Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Antibe Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Antibe Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antibe Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's Shiller PE Ratio falls into.



Antibe Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Antibe Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Antibe Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.055/125.0724*125.0724
=-0.055

Current CPI (Dec. 2023) = 125.0724.

Antibe Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.195 98.604 -0.247
201406 -0.272 99.473 -0.342
201409 -0.211 99.394 -0.266
201412 -0.141 98.367 -0.179
201503 -0.366 99.789 -0.459
201506 -0.072 100.500 -0.090
201509 -0.134 100.421 -0.167
201512 -0.067 99.947 -0.084
201603 -0.204 101.054 -0.252
201606 -0.069 102.002 -0.085
201609 -0.068 101.765 -0.084
201612 -0.142 101.449 -0.175
201703 -0.140 102.634 -0.171
201706 -0.134 103.029 -0.163
201709 -0.068 103.345 -0.082
201712 -0.066 103.345 -0.080
201803 -0.125 105.004 -0.149
201806 -0.065 105.557 -0.077
201809 -0.066 105.636 -0.078
201812 -0.131 105.399 -0.155
201903 -0.132 106.979 -0.154
201906 -0.067 107.690 -0.078
201909 -0.137 107.611 -0.159
201912 -0.103 107.769 -0.120
202003 -0.149 107.927 -0.173
202006 -0.105 108.401 -0.121
202009 -0.148 108.164 -0.171
202012 -0.109 108.559 -0.126
202103 -0.087 110.298 -0.099
202106 -0.088 111.720 -0.099
202109 -0.114 112.905 -0.126
202112 -0.062 113.774 -0.068
202203 -0.079 117.646 -0.084
202206 -0.074 120.806 -0.077
202209 -0.091 120.648 -0.094
202212 -0.056 120.964 -0.058
202303 -0.041 122.702 -0.042
202306 -0.076 124.203 -0.077
202309 -0.069 125.230 -0.069
202312 -0.055 125.072 -0.055

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Antibe Therapeutics  (STU:4B70) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Antibe Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Antibe Therapeutics (STU:4B70) Business Description

Traded in Other Exchanges
N/A
Address
15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2
Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.

Antibe Therapeutics (STU:4B70) Headlines

No Headlines